Related Experiment Video

Updated: Feb 20, 2026

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

11.1K

Combination immunotherapy strategies in advanced non-small cell lung cancer (NSCLC): Does biological rationale meet

Ilaria Attili1, Antonio Passaro2, Alberto Pavan1

  • 1Medical Oncology 2, Istituto Oncologico Veneto IRCCS, Padova, Italy; Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.

Critical Reviews in Oncology/Hematology
|October 26, 2017
PubMed

Insights

Immune checkpoint inhibitors (ICIs) improve advanced non-small cell lung cancer (NSCLC) treatment but have limited response rates. This review explores novel combination strategies to enhance ICI efficacy in NSCLC.

Area of Science:

  • Oncology
  • Immunotherapy

Background:

  • Immune checkpoint inhibitors (ICIs) are a key therapy for advanced non-small cell lung cancer (NSCLC).
  • Current ICI response rates are limited (≤45%) due to biomarker limitations and tumor microenvironment complexity.
  • Tumor immune evasion strategies necessitate novel therapeutic approaches.

Purpose of the Study:

  • To review the biological rationale and early clinical data for combination strategies involving ICIs in NSCLC.
  • To analyze combinations of ICIs with other ICIs, chemotherapy, tyrosine kinase inhibitors, antiangiogenic agents, and radiotherapy.

Main Methods:

  • Literature review of biological rationale.
  • Analysis of early clinical data for various ICI combination therapies.

Main Results:

  • Various combination strategies are being investigated to overcome ICI resistance.
  • Combinations include ICI-ICI, ICI-chemotherapy, ICI-tyrosine kinase inhibitors, ICI-antiangiogenic agents, and ICI-radiotherapy.

Conclusions:

  • Combination therapies hold promise for improving outcomes in advanced NSCLC patients treated with ICIs.
  • Further research is needed to optimize these novel therapeutic strategies.
Keywords:
Antiangiogenic treatmentCTLA-4Combination treatmentIDOImmune checkpointLAG-3Lung cancerPD-L1

More Related Videos

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.8K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

1.4K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.2K